一分钟看懂
这是一项关于Recurrent Lung Non-Small Cell Carcinoma的I 期 / II 期研究，登记的药物或干预包括Image Guided Radiation Therapy；Intensity-Modulated Radiation Therapy；Laboratory Biomarker Analysis；Photon Beam Radiation Therapy；Proton Beam，当前状态为研究进行中，已停止招募。登记地点显示中国Houston有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Image Guided Radiation Therapy；Intensity-Modulated Radiation Therapy；Laboratory Biomarker Analysis；Photon Beam Radiation Therapy；Proton Beam Radiation Therapy；Questionnaire Administration · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- M D Anderson Cancer Center · Houston
公开的入选条件
- * Pathologically proven diagnosis of unresected stage II-IIIB, or recurrent after surgical resection or stereotactic body radiation therapy (SBRT) non-small cell lung cancer
- * Suitability for concurrent chemoradiation therapy per treating physician's assessment
- * Karnofsky performance status (KPS) score \>= 70
- * Weight loss \< 15% in the 3 months before diagnosis
- * Prior receipt of induction chemotherapy followed by referral for concurrent chemoradiation is allowed
- * Adequate lung function indicated by forced expiratory volume at 1 second (FEV1) \>= 1 L is required
- * The primary tumor and/or regional lymph nodes must be evaluable radiographically
- * The gross target volume (GTV) is suitable for motion management using 4 dimensional computed tomography (4D CT), internal target volume (ITV), or respiratory gating; in addition, the target coverage and normal tissue constraints must be met as specified in p
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT01629498；登记信息更新于 2026-09-16。